Premium
Effects of mogamulizumab in adult T‐cell leukemia/lymphoma in clinical practice
Author(s) -
Sekine Masaaki,
Kubuki Yoko,
Kameda Takuro,
Takeuchi Masanori,
Toyama Takanori,
Kawano Noriaki,
Maeda Kouichi,
Sato Seiichi,
Ishizaki Junzo,
Kawano Hiroshi,
Kamiunten Ayako,
Akizuki Keiichi,
Tahira Yuki,
Shimoda Haruko,
Shide Kotaro,
Hidaka Tomonori,
Kitanaka Akira,
Yamashita Kiyoshi,
Matsuoka Hitoshi,
Shimoda Kazuya
Publication year - 2017
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12863
Subject(s) - medicine , rash , refractory (planetary science) , lymphoma , adult t cell leukemia/lymphoma , adverse effect , toxicity , clinical trial , leukemia , t cell leukemia , physics , astrobiology
Objective The efficacy of mogamulizumab in adult T‐cell leukemia/lymphoma ( ATLL ) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real‐life settings have demonstrated worse outcomes. Method We retrospectively analyzed 96 patients with relapsed/refractory ATLL who received mogamulizumab treatment. Results Relapsed/refractory ATLL patients with a median age of 70 years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression‐free survival ( PFS ) and overall survival ( OS ) from the start of mogamulizumab therapy were 1.8 and 4.0 months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median PFS and OS durations of 2.7 and 8.5 months, respectively. The median OS from diagnosis in relapsed/refractory ATLL patients receiving mogamulizumab was 12 months, longer than the 5.8 months in a historical cohort without mogamulizumab. Conclusion In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed/refractory ATLL , with an acceptable toxicity profile. Mogamulizumab therapy improved the OS of ATLL patients.